Long-term efficacy of Chelsea drug may pose problems for FDA
January 10, 2014 at 09:01 AM EST
Jan 10 (Reuters) - A treatment developed by Chelsea Therapeutics International Ltd for a rare type of low blood pressure is presenting problems for U.S. drug reviewers at the U.S. Food and Drug Administration.
